Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, Erickson R, Chiu H, Reed C, Chung S, Neufert C, Atreya I, Mcbride J, Neurath M, Zundler S (2019)
Publication Type: Journal article
Publication year: 2019
Journal
Book Volume: 10
Article Number: 39
Abstract
Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-beta 7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in several phase III trials. Mechanistically, etrolizumab is known to block beta 7 integrin ligand binding and reduces intestinal trafficking of beta 7-expressing cells. Etrolizumab blocks beta 7 integrin ligand binding and reduces beta 7-positive lymphocyte migration and retention in the inflamed gut mucosa, but the exact mechanisms by which this inhibition occurs are not fully understood.
Authors with CRIS profile
Philipp Tripal
Optical Imaging Center Erlangen (OICE)
Raja Atreya
Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)
Clemens Neufert
Medizinische Fakultät
Markus Neurath
Lehrstuhl für Innere Medizin I
Sebastian Zundler
Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology
Additional Organisation(s)
Related research project(s)
Involved external institutions
United States (USA) (US)How to cite
APA:
Lichnog, C., Klabunde, S., Becker, E., Fuh, F., Tripal, P., Atreya, R.,... Zundler, S. (2019). Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Frontiers in Pharmacology, 10. https://doi.org/10.3389/fphar.2019.00039
MLA:
Lichnog, Charlotte, et al. "Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease." Frontiers in Pharmacology 10 (2019).
BibTeX: Download